drugset / Trial / NCT06601192

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

NCT06601192

Phase 1 Completed 72 enrolled Enanta Pharmaceuticals, Inc
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.

Timeline

Start
2024-07-15
Primary completion
2025-02-02
Completion
2025-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule
Subject zelicapavir Small molecule